This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-06-2033v1 0008-5472.CAN-06-2033v2 66/16/7840    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joazeiro, C. A.P. Articles by Hunter, T. Search for Related Content PubMed PubMed Citation Articles by Joazeiro, C. A.P. Articles by Hunter, T.

Proteasome Inhibitor Drugs on the Rise

¹ Genomics Institute of the Novartis Foundation and The Scripps Research Institute; ² Salk Institute for Biological Studies, San Diego, California; and ³ Dana-Farber Cancer Institute, Boston, Massachusetts

Requests for reprints: Claudio A.P. Joazeiro, Genomics Institute of the Novartis Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121. Phone: 858-812-1712; E-mail: cjoazeiro{at}hotmail.com.

In May 2003, the U.S. Food and Drug Administration granted the proteasome inhibitor bortezomib (Velcade) fast-track status for the treatment of multiple myeloma. This landmark represented the first approval of a drug targeting the ubiquitin-proteasome system (UPS) for any indication. More recently, at the AACR Special Conference "Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic" (Orlando, FL, January 18-22, 2006), it became evident that drug discovery in the UPS is experiencing another round of great excitement. The reason—new clinical applications found for bortezomib, along with the promised success of new types of proteasome inhibitors reaching the clinic. (Cancer Res 2006; 66(16): 7840-2)

This article has been cited by other articles:

				R. Oerlemans, N. E. Franke, Y. G. Assaraf, J. Cloos, I. van Zantwijk, C. R. Berkers, G. L. Scheffer, K. Debipersad, K. Vojtekova, C. Lemos, et al. Molecular basis of bortezomib resistance: proteasome subunit {beta}5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood, September 15, 2008; 112(6): 2489 - 2499. [Abstract] [Full Text] [PDF]

				A. Shanker, A. D. Brooks, C. A. Tristan, J. W. Wine, P. J. Elliott, H. Yagita, K. Takeda, M. J. Smyth, W. J. Murphy, and T. J. Sayers Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody J Natl Cancer Inst, May 7, 2008; 100(9): 649 - 662. [Abstract] [Full Text] [PDF]

				W. Li, G. Wu, and Y. Wan The dual effects of Cdh1/APC in myogenesis FASEB J, November 1, 2007; 21(13): 3606 - 3617. [Abstract] [Full Text] [PDF]

				T. Subramanian, S. Vijayalingam, E. Lomonosova, L.-j. Zhao, and G. Chinnadurai Evidence for Involvement of BH3-Only Proapoptotic Members in Adenovirus-Induced Apoptosis J. Virol., October 1, 2007; 81(19): 10486 - 10495. [Abstract] [Full Text] [PDF]

				C. Marx, C. Yau, S. Banwait, Y. Zhou, G. K. Scott, B. Hann, J. W. Park, and C. C. Benz Proteasome-Regulated ERBB2 and Estrogen Receptor Pathways in Breast Cancer Mol. Pharmacol., June 1, 2007; 71(6): 1525 - 1534. [Abstract] [Full Text] [PDF]

				R. Fonseca and A. K. Stewart Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach Mol. Cancer Ther., March 1, 2007; 6(3): 802 - 810. [Abstract] [Full Text] [PDF]

				P. N. Yadav, K. Chaturvedi, and R. D. Howells Inhibition of Agonist-Induced Down-Regulation of the {delta}-Opioid Receptor with a Proteasome Inhibitor Attenuates Opioid Tolerance in Human Embryonic Kidney 293 Cells J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1186 - 1194. [Abstract] [Full Text] [PDF]